Rhythm Pharmaceuticals Financials - Benzinga

Rhythm Pharmaceuticals Inc

RYTMNASDAQ

Trade with Public

Trade with Public

$110.54

-5.19-4.48%

Last update: Aug 20, 12:09 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Rhythm Pharmaceuticals Financials

Rhythm Pharmaceuticals (RYTM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Rhythm Pharmaceuticals Q2 EPS $(0.73) Beats $(0.82) Estimate, Sales $71.255M Beat $67.277M Estimate

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 2.67 percent increase over losses of $(0.75) per share

Benzinga Newsdesk

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.

Avi Kapoor

Earnings Scheduled For May 5, 2026

Benzinga Insights

PRO
Rhythm Pharmaceuticals Anticipates Approximately $385M-$415M In Non-GAAP Operating Expenses In Fiscal 2026

Benzinga Newsdesk

PRO
Rhythm Pharmaceuticals Q1 EPS $(0.83) Beats $(0.84) Estimate, Sales $60.112M Beat $55.776M Estimate

Benzinga Newsdesk

Stock Market Today: Dow, S&P 500 Futures Tick Up As Oil Prices Rise, US Allies Reject Trump's Hormuz Call— Uber, Lululemon, Cisco In Focus (UPDATED)

(Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the headline were updated in the story.) Dow Jones and S&P 500 futures pared earlier losses to trade slightly up on Tuesday, while Nasdaq futures were trading lower following Monday’s gains. Futures of the major benchmark indices were mixed.

Rishabh Mishra